Mainland China announced it will import at least 100 million German vaccines next year | Chinese communist virus | National vaccines | Buy German vaccines

[La Gran Época, 17 de diciembre de 2020]The Chinese Communist Party virus epidemic (Wuhan pneumonia) broke out on a large scale around the world. Many Western countries have invested heavily in accelerating vaccine development, clinical trials, production and distribution. Although many pharmaceutical companies in mainland China have developed a vaccine for Wuhan pneumonia, they have yet to receive final approval. Shanghai Fosun Pharma announced that it will import at least 100 million vaccines from German biotech BioNTech next year.

Last month, German biotech company BioNTech and Pfizer announced that analysis of third-phase interim data from the mRNA (messenger ribonucleic acid) vaccine they developed showed that the vaccine (BNT162b2, working name “Fubitai”) has a protective effect of 90%, which is higher than the 50% required by the US Food and Drug Administration.

Fubitai is the world’s first Chinese virus vaccine to publish phase III clinical data. The vaccine began phase III clinical trials in early August. Current data shows that the effective rate of the second dose of vaccine is greater than 90% 7 days after vaccination.

Currently, BioNTech and Pfizer vaccines have been licensed for emergency use in the United States, United Kingdom, and other countries.

Jiemian News reported that Shanghai Fosun Pharmaceutical Group owns the rights and interests of the vaccine in the Chinese market, and the two sides signed a related cooperation agreement in March this year.

Reuters and other foreign media reported that Fosun Pharma issued a statement to the Hong Kong Stock Exchange on December 16 that BioNTech will provide China with no less than 100 million doses of vaccine in 2021. Fosun paid 250 million euros for the first batch of 50 million doses.

Currently, four vaccines in mainland China are in the final testing stage. However, the Peruvian Health Ministry said on December 12 that because a volunteer had a health problem, it had suspended clinical trials of the China Bio-Wuhan pneumonia vaccine “Sinopharm Group” in the country.

According to the Wall Street Journal, Dr. Germán Málaga, a researcher at the Cayetano Heredia University in Peru, who conducted the vaccine trial, said that a 64-year-old volunteer had complications with “neurological symptoms” and had some strength in the legs. Refusal, there are some problems with the stock.

In mainland China, more than a million people have been vaccinated with household vaccines, but the process is discreet. Residents in Beijing, Shanghai and elsewhere told Radio Free Asia that they had not yet heard of the vaccination, but interviewees said they were concerned about the quality of the vaccine and refused to receive it.

Vaccine management in China is chaotic: In the last decade, thousands of children have been sickened, injured or died after being immunized. For example, the Shanxi vaccine incident in 2007 resulted in nearly 100 children being injured or killed. In 2018, in the Longevity DPT vaccine incident, 250,000 inferior vaccines entered the market.

Editor in Charge: Fang Xiao